CIC
HAE icon

Chilton Investment Company’s Haemonetics HAE Stock Holding History

Chilton Investment Company’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-232,045
Closed -$17M – 141
2018
Q1 		$17M Buy
232,045
+14,220
+7% +$976K 0.65% 40
2017
Q4 		$12.7M Buy
217,825
+45,081
+26% +$2.37M 0.49% 39
2017
Q3 		$7.75M Buy
+172,744
New +$7.18M 0.3% 53

Other funds holding HAE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Chilton Investment Company's HAE Position: Q2 2018 in Review

Chilton Investment Company sold out of Haemonetics (HAE) in Q2 2018, closing a stake of 232,045 shares — an estimated $17M sold.

Chilton Investment Company first reported a position in HAE in Q3 2017 and held it in 3 quarters. The position peaked at $17M in Q1 2018. 293 funds tracked by Wall St. Rank hold HAE as of Q2 2018.

  • Chilton Investment Company reported no remaining Haemonetics position as of Q2 2018 after selling out during the quarter.
  • Chilton Investment Company sold 232,045 Haemonetics shares in Q2 2018, an estimated $17M.
  • Chilton Investment Company first reported a position in Haemonetics in Q3 2017 and held it in 3 quarters.
  • Chilton Investment Company's Haemonetics position peaked at $17M in Q1 2018.
  • 293 funds tracked by Wall St. Rank held Haemonetics as of Q2 2018.

Based on Chilton Investment Company's 13F filing for Q2 2018, filed 10 Aug 2018.